homevideos Newsmarket Newsstocks News

Raw material prices softening; aim to double EBITDA in next 2 3 years: Rossari Biotech

videos | Mar 31, 2022 2:49 PM IST

Raw material prices softening; aim to double EBITDA in next 2-3 years: Rossari Biotech

Mini

Rossari Biotech has corrected 30 percent in last 3 months. Sunil Chari, Co-founder & MD of Rossari Biotech in an interview to CNBC-TV18 said, margins are likely to increase from Q2FY23 as prices for main raw materials have started declining.

Rossari Biotech has corrected 30 percent in last 3 months.

Recommended Articles

View All

Sunil Chari, Co-founder & MD of Rossari Biotech in an interview to CNBC-TV18 said, margins are likely to increase from Q2FY23 as prices for main raw materials have started declining.
He said the company expects to do Rs 1,600 crore of revenue in FY22 and double the EBITDA in next 2-3 years.
Watch video for more.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng